Axovant discontinues development of nelotanserin after Phase II readout

Axovant Sciences Ltd. (NASDAQ:AXON) discontinued development of nelotanserin after the product missed the primary endpoint in a Phase II trial to treat REM sleep behavior disorder in patients with Lewy body dementia.

The double-blind trial enrolled 34 patients and evaluated a primary endpoint of the change from baseline in the frequency of REM sleep behavior disorder events as measured by sleep laboratory video assessment at day 28 vs. placebo. Nelotanserin is an inverse agonist of the serotonin (5-HT2A) receptor...